首页> 外文期刊>American Journal of Transplantation >Duodenal Villous Atrophy: A Cause of Chronic Diarrhea After Solid-Organ Transplantation
【24h】

Duodenal Villous Atrophy: A Cause of Chronic Diarrhea After Solid-Organ Transplantation

机译:十二指肠绒毛萎缩:固体器官移植后慢性腹泻的原因

获取原文
获取原文并翻译 | 示例
           

摘要

Persistent diarrhea is commonly observed after solid organ transplantation (SOT). A few cases of mycophenolate mofetil (MMF)-induced duodenal villous atrophy (DVA) have been previously reported in kidney-transplant patients with chronic diarrhea. Herein, we report on the incidence and characteristics of DVA in SOT patients with chronic diarrhea. One hundred thirty-two SOT patients with chronic diarrhea underwent an oesophago-gastroduodenoscopy (OGD) and a duodenal biopsy after classical causes of diarrhea have been ruled out. DVA was diagnosed in 21 patients (15.9%). It was attributed to mycophenolic acid (MPA) therapy in 18 patients (85.7%) (MMF [n = 14] and enteric-coated mycophenolate sodium [n = 4]). MPA withdrawal or dose reduction resulted in diarrhea cessation. The incidence of DVA was significantly higher in patients with chronic diarrhea receiving MPA compared to those who did not (24.6% vs. 5.1%, p = 0.003). DVA was attributed to a Giardia lamblia parasitic infection in two patients (9.5%) and the remaining case was attributed to azathioprine. In these three patients, diarrhea ceased after metronidazole therapy or azathioprine dose reduction. In conclusion, DVA is a frequent cause of chronic diarrhea in SOT recipients. MPA therapy is the most frequent cause of DVA. An OGD should be proposed to all transplant recipients who present with persistent diarrhea.
机译:实体器官移植(SOT)后通常观察到持续性腹泻。先前已经有几例霉酚酸酯引起的十二指肠绒毛萎缩(DVA)在慢性腹泻的肾移植患者中报道。在本文中,我们报告了SOT慢性腹泻患者中DVA的发生率和特征。在排除经典的腹泻病因后,对132例慢性腹泻的SOT患者进行了食管-胃十二指肠镜检查(OGD)和十二指肠活检。在21例患者中诊断出DVA(15.9%)。它归因于18例患者(85.7%)的霉酚酸(MPA)治疗(MMF [n = 14]和肠溶性霉酚酚钠[n = 4])。停用MPA或减少剂量可导致腹泻停止。与未接受MPA的慢性腹泻患者相比,接受MPA的慢性腹泻患者的DVA发生率显着更高(24.6%比5.1%,p = 0.003)。 DVA归因于两名患者(9.5%)的贾第鞭毛虫寄生虫感染,其余病例归因于硫唑嘌呤。在这三例患者中,甲硝唑治疗或减少硫唑嘌呤剂量后腹泻停止。总之,DVA是SOT接受者慢性腹泻的常见原因。 MPA治疗是DVA的最常见原因。应向所有持续腹泻的移植受者建议使用OGD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号